User profiles for T. Witzig

Thomas Witzig, MD

Professor of Medicine, Mayo Clinic
Verified email at mayo.edu
Cited by 80494

International consensus guidance statement on the management and treatment of IgG4‐related disease

…, H Umehara, GJ Webster, TE Witzig… - Arthritis & …, 2015 - Wiley Online Library
IgG4-related disease (IgG4-RD) is an immunemediated fibroinflammatory condition that can
affect multiple organs and lead to tumefactive, tissuedestructive lesions and organ failure (1)…

Targeting apoptosis pathways in cancer therapy

IM Ghobrial, TE Witzig, AA Adjei - CA: a cancer journal for …, 2005 - Wiley Online Library
… The Bcl-2 family are key regulators of apoptosis and are overexpressed in many
malignancies even without the presence of the t (14; 18) chromosomal translocations. Increased …

[HTML][HTML] International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

…, R Advani, N Valente, C Fortpied, TE Witzig… - Annals of …, 2017 - Elsevier
… For a subject let X ti denote the maximal diameter for lesion i at scan time t and Y ti the … is
X t 1 + ⋯ + X t k and the bi-dimensional measurement is X t 1 Y t 1 + ⋯ + X t k Y t k , where k is …

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

…, TM Therneau, PR Greipp, TE Witzig… - Journal of clinical …, 2004 - ascopubs.org
… Our group previously identified elevated serum cardiac troponin T (cTnT) as the most
powerful predictor of overall survival. Others have reported that N-terminal pro-brain natriuretic …

[HTML][HTML] Effective surgical adjuvant therapy for high-risk rectal carcinoma

…, RF Morton, MH Veeder, TE Witzig… - … England Journal of …, 1991 - Mass Medical Soc
Background Radiation therapy as an adjunct to surgery for rectal cancer has been shown to
reduce local recurrence but has not improved survival. In a previous study, combined …

Review of 1027 patients with newly diagnosed multiple myeloma

RA Kyle, MA Gertz, TE Witzig, JA Lust, MQ Lacy… - Mayo clinic …, 2003 - Elsevier
Objective To determine the clinical and laboratory features of newly diagnosed multiple
myeloma. Patients and Methods Records of all patients in whom multiple myeloma was initially …

POEMS syndrome: definitions and long-term outcome: Presented in abstract form at the 41st annual meeting of the American Society of Hematology, New Orleans, LA …

…, DR Larson, PR Greipp, TE Witzig… - Blood, The Journal …, 2003 - ashpublications.org
The POEMS syndrome (coined to refer to polyneuropathy, organomegaly, endocrinopathy,
M protein, and skin changes) remains poorly understood. Ambiguity exists over the features …

[HTML][HTML] A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

RA Kyle, MA Gertz, PR Greipp, TE Witzig… - … England Journal of …, 1997 - Mass Medical Soc
Background Primary systemic amyloidosis is an uncommon disease characterized by the
accumulation in vital organs of a fibrillar protein consisting of monoclonal light chains. Methods …

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus …

…, MT Drake, P Kapoor, SM Ansell, TE Witzig… - Mayo Clinic …, 2013 - Elsevier
Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than
20,000 people annually in the United States. There has been a veritable revolution in this …

Rituximab for IgG4-related disease: a prospective, open-label trial

…, MD Topazian, A Khosroshahi, TE Witzig… - Annals of the …, 2015 - ard.bmj.com
… to T cells and/or the synthesis of cytokines that sustain T cell memory.4 ,27 The response
to RTX among patients with IgG4-RD appears to be variable, with some patients having …